The 6th Health Economics Forum 2022

Emerging Opportunities: Recalibrating the Value of Healthcare


2022 heralds the return of the Health Economics Forum in Malaysia.

This year, it is an in-person-only event that encourages connecting and talking after two years of silence, online webinars and teleconferencing.

In a post-pandemic environment, the event has become even more pertinent when addressing the future of healthcare for all. 



This year, the Health Economic Outcome Research (hEOR) and co-organisers, the Ministry of Health Malaysia and PhAMA (Pharmaceutical Association of Malaysia), look forward to facilitating dialogues in a “virtuous cycle” of debate on multiple topics.

The 6th Health Economics Forum 2022 will engage various stakeholders, experts, scholars and adept practitioners of Health Economics in crisis response, fundamentals of efficiency and sustainability by looking at Health Technology Assessments in strained systems.

The Forum will highlight innovation, access, value and affordability.

The 2022 edition features the legendary Professor Michael Drummond in a plenary session, “Value Assessment and Pursuing Innovation and Access in the Pandemic”. He will also share updates on CHEERS 2.0 – what is new in Health Economics evaluation guidelines.

The Forum also brings a senior professor of Health Economics at Ghent University, a former advisor to the Belgian Minister of Health, and one of Europe’s leading experts in health economics and Health Technology Assessment, Professor Lieven Annemans.

There’s an intense debate about the prices of innovative medicines. Are value-based prices the solution? Professor Annemans will share his perspective at the Forum.


After two years, change is inevitable but necessary. So let us talk about this.

Join us from November 23-24 at Hilton Hotel Petaling Jaya!










Previous editions of the Health Economic Forum


  • 2019: “An Efficient and Sustainable Healthcare System in Malaysia: The Challenges, Lessons and Future”. The 2019 Forum was the fifth installation of the very successful annual Forum event since 2013. The Forum has progressed and established itself as one of the most anticipated events on the local pharmaceutical industry calendar. The event featured some of the most prominent figures in the field of Health Economics, such as Emeritus Professor Adrian Towse from the Office of Health Economics (UK), Professor Mark Sculpher from University of York (UK), Professor Phua from Lee Kuan Yew School of Public Policy, National University of Singapore, and Professor SC Li from University of Newcastle (Australia). The Forum was supported by partners; Johnson & Johnson (M), Pfizer (M), Servier (M), Merck Sharp & Dohme(M), and IQVIA.


  • 2017: “The Role of Health Economics and Health Technology Assessment (HTA) in Establishing Value and Market Access for New Pharmaceuticals”. The workshop was conducted together with Professor Michael Drummond (University of York), Professor Kenneth Lee (Monash University Malaysia), Dr June Choon (Monash University Malaysia) and Dr David Wu (Agency for Care Effectiveness, Singapore). The event was supported by partners; Pfizer Sdn Bhd and Johnson and Johnson Sdn Bhd, and co-organizer, Pharmaceutical Association of Malaysia (PhAMA).


  • 2016: “Evidence-based Pricing and Access Schemes for New Pharmaceuticals: Future for Malaysia?Many leading voices in the industry were invited – from both private and the government – to engage in a discourse on the challenges and implications of using evidence-based approach as a method of setting priorities for the utilization of health resources. The Forum featured Professor Michael Drummond, from the Centre for Health Economics, University of York as the keynote speaker.


  • 2015: “Access to Medicine by an Evidence-based Approach aimed at providing an overview of government initiatives within the healthcare industry and the implications to healthcare providers. The forum highlighted lessons from other countries in using Health Technology Assessment (HTA) and how the implementation of HTA would work in the Malaysian healthcare system.

  • 2013: “Evidence-based Pricing and Access Schemes for New Pharmaceuticals: Future for Malaysia


  • 2014: “Value of Medicines: Patient’s and Healthcare Professional’s Perspective



23 - 24 Nov 2022


All Day


Hilton Petaling Jaya
2, Jalan Barat, Pjs 52, 46200 Petaling Jaya, Selangor, Malaysia


Health Economics Outcomes Research
+6012 336 2338
[email protected]

Featured Speakers

  • Dr. Khor Swee Kheng
    Dr. Khor Swee Kheng
    Senior Visiting Fellow, United Nations University

    Swee Kheng is a physician currently specializing in health systems and global health, holding fellowships at Chatham House and the United Nations University (UNU-IIGH). He is also the founder-CEO of Angsana Health (a primary healthcare start-up in Malaysia) and cofounder-coordinator of the Malaysian Health Coalition (an advocacy group comprising 53 professional societies and associations).

    Previously, he held progressively senior practitioner roles in clinical medicine, refugee & disaster relief, clinical research and pharma anti-corruption. In these roles, he was based in Malaysia, Singapore, Dubai, Shanghai and Paris, covering >90 countries across Asia, Africa, Europe and the Middle East.

    Swee Kheng (or SK) holds three postgraduate degrees, in internal medicine (RCP UK), public health (Berkeley) and public policy (Oxford). He has published articles, reports and book chapters in international media, think-tanks and academic journals.

  • Prof. Michael Drummond
    Prof. Michael Drummond
    Professor of Health Economics, University of York

    Michael Drummond, is Professor of Health Economics and former Director of the Centre for Health Economics at the University of York. He is the author of two major textbooks and more than 700 scientific papers, and has acted as a consultant to the World Health Organization and the European Union.

    He has been President of the International Society of Technology Assessment in Health Care, and the International Society for Pharmacoeconomics and Outcomes Research. In October 2010 he was made a member of the National Academy of Medicine in the USA. He has advised several governments on the assessment of health technologies and chaired one of the Guideline Review Panels for the National Institute for Health and Care Excellence (NICE) in the UK.

    He is currently Co-Editor-in-Chief of Value in Health and has been awarded 3 honorary doctorates, from City University (London), Erasmus University (Rotterdam) and the University of Lisbon.

  • Prof. Lieven Annemans
    Prof. Lieven Annemans
    Senior Full Professor of Economics of Health and Wellbeing, Ghent University

    Lieven Annemans is Senior Full Professor of Economics of Health and Wellbeing at the Faculty of medicine and health sciences at Ghent University, Belgium. He is Past-President of ISPOR (the International Society of PharmacoEconomics and Outcomes Research), was during 8 years chairman of the Flemish health council, and is currently chairman of the Flemish Committee for Societal Revival.

    He conducts research on how to opitmize the health of the population since more than 25 years, specialising in Health Technology Assessment (HTA) and the cost-effectveness of health promotion.

    Since 6 years he also conducts research on happiness among the general population and among patients. He is (co-) author of > 300 scientific papers in peer-reviewed journals and published several books, among which ‘Health economics for non-economists’ (Pelckmans Pro, 2018) and ‘Geluk vinden zonder het te zoeken’ (Finding happiness without pursuit) – Borgerhoff & Lamberigts, 2020.

  • Prof Asrul A Shafie
    Prof Asrul A Shafie
    Professor of Pharmacoeconomic & Director for Institutional Planning & Strategic Centre, Universiti Sains Malaysia

    Asrul A Shafie completed his PhD degree in 2008. His research interests are in pharmacoeconomic, and health service research where he has published more than 300 peer reviewed journal articles and books/monographs with H-Index of 39. He is the editorial board member for Pharmacoeconomics and Value in Health Asian Region journal. He is currently the Board Member for HTAsiaLink Network, and core member of ISPOR Code of Ethics Task Force. He is also an appointed expert member for the UK National Institute for Health Research Committee, Malaysia Health Technology Assessment Agency (MaHTAS), Malaysia Pharmacoeconomic Guidelines Development Committee, Malaysia Institute of Health Service Research, Malaysia Pharmacy Advisory Board and Malaysia Pharmacoeconomic Technical Committee. At present, Dr Asrul is the Professor of Pharmacoeconomic and Director for Institutional Planning & Strategic Centre in Universiti Sains Malaysia.

  • Dr. June Choon
    Dr. June Choon
    Principal Science Officer, hEOR

    With more than 10 years of experience in pharmacy, Dr. June Choon began her career as a front-line hospital pharmacist but discovered very early on that her forte lay in academic pharmacy and related scientific research. She has done more than twenty bioavailability and bioequivalence studies for local pharmaceuticals.

    Dr. Choon is a published former academic with Monash University, and in her eight years in tenure, she was appointed as Chair of the Monash Health Economics Forum and drove its knowledge sharing endeavours with support from the Pharmaceutical Services Division, Ministry of Health, Pharmaceutical Association of Malaysia (PhAMA). Her focus research areas have included: cardiovascular, psychiatry, oncology and real-world evidence.

  • Dr. Izzuna Mudla Mohd Ghazali
    Dr. Izzuna Mudla Mohd Ghazali
    Public Health Physician, Ministry of Health

    Dr. Izzuna Mudla Mohamed Ghazali is a Public Health Physician with a specialty in Epidemiology. She is the Head of Horizon Scanning, Communication and Information Unit at Malaysian Health Technology Assessment Section (MaHTAS), Medical Development Division, Ministry of Heath Malaysia.

    Dr. Izzuna joined MaHTAS in 2007 and was given the responsibility to set up horizon scanning of emerging technologies activities for Ministry of Health Malaysia. She is a senior reviewer and has conducted assessment on various health technologies and reviewed assessment conducted by other reviewers.

    Dr. Izzuna is also the liaison officer for MaHTAS in networking with international HTA agencies and has published several articles on public health issues in international journals.

  • Jomo K. S.
    Jomo K. S.
    Visiting Senior Fellow, Khazanah Research Institute

    Jomo Kwame Sundaram is Visiting Senior Fellow at Khazanah Research Institute, Visiting Fellow at the Initiative for Policy Dialogue, Columbia University, and Adjunct Professor at the International Islamic University in Malaysia.

    ​He was Assistant Director General and Coordinator for Economic and Social Development (ADG-ES), Food and Agriculture Organization of the United Nations from August 2012 until December 2015. He was Assistant Secretary General for Economic Development in the United Nations’ Department of Economic and Social Affairs (DESA) from January 2005 until June 2012, and (Honorary) Research Coordinator for the G24 Intergovernmental Group on International Monetary Affairs and Development from December 2006 until September 2012.

    In 2007, he was awarded the Wassily Leontief Prize for Advancing the Frontiers of Economic Thought. He has authored and edited over a hundred books and translated ten volumes besides writing many academic papers and articles for the media.